RÉSUMÉ
OBJECTIVE: The lactulose-to-mannitol ratio test is a test to assess the disorders associated with gut permeability. The test requires an oral administration of the mixture of lactulose and mannitol and urine collection. The urinary ratio of lactulose to mannitol is an indicator of intestinal permeability. Due to the complexity of urine collection in animal studies, plasma exposure ratios of lactulose to mannitol compared to their urinary concentration ratios were evaluated following an oral administration of the sugar mixture in pigs. ANIMALS: 10 pigs were orally dosed with a solution of lactulose and mannitol mixture. PROCEDURES: Plasma samples were collected at predose, 10 and 30 minutes and 2, 4, and 6 hours postdosing, and cumulated urinary samples were collected at 6 hours for liquid chromatography-mass spectrometry analysis. The ratios of pharmacokinetic parameters of lactulose to mannitol and the plasma sugar ratios at a single time point or the mean values of several time points were compared to their urinary sugar ratios. RESULTS: The results revealed that the lactulose-to-mannitol ratios of AUC0-6h, AUCextrap, and Cmax were correlated to the urinary sugar ratios, and the plasma sugar ratios of a single time point at 2, 4, or 6 hours and the mean values of those time points were also appropriate to replace their urinary ratios in pigs. CLINICAL RELEVANCE: Following an oral administration of lactulose and mannitol mixture, blood collection, and assay can be an option for assessing intestinal permeability, especially in animal studies.
Sujet(s)
Muqueuse intestinale , Lactulose , Animaux , Suidae , Muqueuse intestinale/métabolisme , Lactulose/pharmacocinétique , Lactulose/urine , Administration par voie orale , Mannitol/pharmacocinétique , Mannitol/urine , Perméabilité , Absorption intestinaleRÉSUMÉ
BACKGROUND: Pharmacokinetic and pharmacodynamic assessment of ester-containing drugs can be impacted by hydrolysis of the drugs in plasma samples post blood collection. The impact is different in the plasma of different species. OBJECTIVE: This study evaluated the stability of a prodrug, ketoprofen methylester (KME), in commercially purchased and freshly collected plasma of mouse, rat, dog, cat, pig, sheep, cattle and horse. METHODS: KME hydrolysis was determined following its incubation in commercially purchased and freshly collected plasma of those species. Different esterase inhibitors were evaluated for prevention of the hydrolysis in rat, dog and pig plasma. RESULTS: KME was rapidly hydrolyzed in both commercially purchased and freshly collected plasma of mouse, rat, and horse. The hydrolysis was initially quick and then limited in cat plasma. KME hydrolysis was minimum in commercially purchased plasma of dog, pig, sheep and cattle but substantial in freshly collected plasma of those species. Different esterase inhibitors showed different effects on the stability of KME in rat, dog and pig plasma. CONCLUSION: These results indicate that plasma of different species has different hydrolytic activities to estercontaining drugs. The activities in commercially purchased and freshly collected plasma may be different and species-dependent. Esterase inhibitors have different effects on preventing hydrolysis of the ester-containing drugs in the plasma of different species.
Sujet(s)
Kétoprofène/analogues et dérivés , Animaux , Chats , Bovins , Chimie pharmaceutique , Chiens , Évaluation préclinique de médicament/méthodes , Stabilité de médicament , Femelle , Equus caballus , Hydrolyse , Kétoprofène/administration et posologie , Kétoprofène/composition chimique , Kétoprofène/pharmacocinétique , Mâle , Souris , Promédicaments/administration et posologie , Promédicaments/composition chimique , Promédicaments/pharmacocinétique , Rats , Ovis , Spécificité d'espèce , SuidaeRÉSUMÉ
BACKGROUND: There has been a lack of information about the inhibition of bovine medicines on bovine hepatic CYP450 at their commercial doses and dosing routes. OBJECTIVE: The aim of this work was to assess the inhibition of 43 bovine medicines on bovine hepatic CYP450 using a combination of in vitro assay and Cmax values from pharmacokinetic studies with their commercial doses and dosing routes in the literature. METHODS: Those drugs were first evaluated through a single point inhibitory assay at 3 µM in bovine liver microsomes for six specific CYP450 metabolisms, phenacetin o-deethylation, coumarin 7- hydroxylation, tolbutamide 4-hydroxylation, bufuralol 1-hydroxylation, chlorzoxazone 6-hydroxylation and midazolam 1'-hydroxylation. When the inhibition was greater than 20% in the assay, IC50 values were then determined. The potential in vivo bovine hepatic CYP450 inhibition by those drugs was assessed using a combination of the IC50 values and in vivo Cmax values from pharmacokinetic studies at their commercial doses and administration routes in the literature. RESULTS: Fifteen bovine medicines or metabolites showed in vitro inhibition on one or more bovine hepatic CYP450 metabolisms with different IC50 values. Desfuroylceftiour (active metabolite of ceftiofur), nitroxinil and flunixin have the potential to inhibit one of the bovine hepatic CYP450 isoforms in vivo at their commercial doses and administration routes. The rest of the bovine medicines had low risks of in vivo bovine hepatic CYP450 inhibition. CONCLUSION: This combination of in vitro assay and in vivo Cmax data provides a good approach to assess the inhibition of bovine medicines on bovine hepatic CYP450.
Sujet(s)
Inhibiteurs des enzymes du cytochrome P-450/pharmacologie , Cytochrome P-450 enzyme system/métabolisme , Médicaments vétérinaires/pharmacologie , Animaux , Bovins , Céphalosporines/pharmacologie , Clonixine/analogues et dérivés , Clonixine/pharmacologie , Concentration inhibitrice 50 , Microsomes du foie , Nitroxinil/pharmacologieRÉSUMÉ
Amitraz is an acaricide and insecticide widely used in agriculture and veterinary medicine. Although central nervous system (CNS) toxicity is one of major toxicities following oral ingestion of amitraz, the understanding of the cause of the toxicity is limited. This study evaluated the systemic and brain exposure of amitraz and its major metabolites, BTS27271, 2',4'-formoxylidide, and 2,4-dimethylaniline following administration of amitraz in male Sprague-Dawley rats. Significant metabolism of amitraz was observed following the intravenous and oral administration. Amitraz related metabolites were majority of the total exposure observed, especially following oral administration. BTS27271 had higher brain exposure than amitraz and its other metabolites, which was due to low plasma protein binding but high brain tissue binding of BTS27271. Since BTS27271 has similar or higher toxicity and α2-adrenoreceptor agonist potency than amitraz, its exposure in brain tissues may be the major cause of CNS toxicity of amitraz in animals and humans.
Sujet(s)
Acaricides/pharmacocinétique , Encéphale/métabolisme , Insecticides/pharmacocinétique , Toluidines/pharmacocinétique , Administration par voie intraveineuse , Administration par voie orale , Agonistes des récepteurs alpha-2 adrénergiques/métabolisme , Amidines/métabolisme , Animaux , Mâle , Rat Sprague-DawleyRÉSUMÉ
BACKGROUND: Age has a significant impact on activities of hepatic metabolizing enzymes in humans and animals. Flavin-containing Monooxygenase (FMO) and Aldehyde Oxidase (AO) are two important hepatic enzymes. Understanding of the impact of age on these two enzymes is still limited in pigs. OBJECTIVE: The aim of this work was to assess hepatic FMO and AO activities of male domestic pigs at five different ages of 1 day, 2, 5, 10 and 20 weeks. METHODS: Porcine liver microsomes and cytosol were prepared from the livers of male domestic pigs at ages of 1 day, 2, 5, 10 and 20 weeks. FMO activity was assessed using N-oxidation of benzydamine in porcine liver microsomes and AO activity was evaluated using oxidation of O6-benzylguanine in the porcine liver cytosol. RESULTS: Porcine hepatic FMO activity was substantial at the age of 1 day, rapidly increased in 2 weeks, and remained high afterwards. Porcine hepatic AO activity was minimal at the age of 1 day and gradually increased to the maximum in 5 weeks and remained relatively constant to the age of 20 weeks. Porcine hepatic FMO activity is higher than other species, including humans. Age-dependent FMO developmental pattern in porcine liver is different from porcine hepatic CYP450 and human hepatic FMO. Porcine hepatic AO activity is much lower than humans although their developmental patterns are similar. CONCLUSION: Age impact on hepatic activities of both FMO and AO is obvious in domestic male pigs although age patterns of both enzymes are different.
Sujet(s)
Aldehyde oxidase/métabolisme , Foie/enzymologie , Oxygénases/métabolisme , Facteurs âges , Animaux , Benzydamine/métabolisme , Guanine/analogues et dérivés , Guanine/métabolisme , Mâle , Microsomes du foie/enzymologie , Oxydoréduction , Sus scrofaRÉSUMÉ
A novel direct injection gas chromatography method coupled with selective ion monitoring mass spectrometry (GC/SIM-MS) was developed for quantitation of trace levels of high boiling point (HBP) epoxide genotoxic impurity (GTI) in drug substance. The injector temperature was optimized with the aims to minimize matrix effects and enhance SIM signal response. The final injector temperature 160°C was selected after balancing between these two factors. The column screening was conducted as well and MN OPTIMA delta-3 silica capillary column was selected since it showed good peak symmetry without column bleeding. The good linearity was established for the concentration in the range from 0.0045µg/mL to 0.5µg/mL with a R2=0.9999. The limit of detection (LOD) and the limit of quantitation (LOQ) were 0.0014µg/mL and 0.0045µg/mL, respectively. The recovery which ranged from 95.0% to 112.5% could meet the ICH acceptance criteria. The validation results demonstrated the good linearity, precision and accuracy of the method which can be further adopted as an adequate quality control tool for quantitation of epoxide impurity at trace levels in drug substance and drug product.
Sujet(s)
Composés époxy/composition chimique , Chromatographie gazeuse-spectrométrie de masse/méthodes , Limite de détection , Contrôle de qualité , TempératureRÉSUMÉ
Drug interactions due to inhibition of hepatic cytochrome P450 (CYP450) enzymes are not well understood in veterinary medicine. Forty-eight commercial porcine medicines were selected to evaluate their potential inhibition on porcine hepatic CYP450 enzymes at their commercial doses and administration routes. Those drugs were first assessed through a single point inhibitory assay at 3 µM in porcine liver microsomes for six specific CYP450 metabolisms (phenacetin o-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, bufuralol 1-hydroxylation, chlorozoxazone 6-hydroxylation and midazolam 1'-hydroxylation). When the inhibition was > 10% in the single point inhibitory assay, IC50 values (inhibitory concentrations that decrease biotransformation of selected substrate by 50%) were determined. Overall, 17 drugs showed in vitro inhibition on one or more porcine hepatic CYP450 metabolisms with different IC50 values. The potential in vivo porcine hepatic CYP450 inhibition by those drugs was assessed by combining the in vitro data and in vivo Cmax (maximum plasma concentrations from pharmacokinetic studies of the porcine medicines at their commercial doses and administration routes). Three drugs showed high potential inhibition to one or two porcine hepatic CYP450 isoforms at their commercial doses and administration routes, while seven drugs had medium risk and seven had low risk of such in vivo inhibition. These data are useful to prevent potential drug interactions in veterinary medical practice.
Sujet(s)
Inhibiteurs des enzymes du cytochrome P-450/pharmacologie , Cytochrome P-450 enzyme system/métabolisme , Foie/effets des médicaments et des substances chimiques , Microsomes du foie/effets des médicaments et des substances chimiques , Sus scrofa/métabolisme , Animaux , Foie/enzymologie , Mâle , Microsomes du foie/enzymologieRÉSUMÉ
Oral delivery of biopharmaceutics drug disposition classification system (BDDCS) Class II or IV drugs with poor aqueous solubility and poor enzymatic and/or metabolic stability is very challenging. Bay41-4109, a member of the heteroaryldihydropyrimidine (HAP) family, inhibits HBV replication by destabilizing capsid assembly. It pertains to class II of the BDDCS which has a practically insoluble solubility which is 38 µg/mL (LYSA) and the oral delivery resulted in low bioavailability. The purpose of the current research work was to develop and evaluate Bay41-4109 loaded chitosan nanoparticles to increase the solubility and bioavailability for treatment of HBV. The Bay41-4109 nanoparticles were prepared by gelation of chitosan with tripolyphosphate (TPP) through ionic cross-linking. A three-factor three-level central composite design (CCD) was introduced to perform the experiments. A quadratic polynomial model was generated to predict and evaluate the independent variables with respect to the dependent variables. Bay41-4109 was encapsulated in the chitosan nanoparticles were demonstrated by PLM, FTIR, DSC, XRD and TEM etc. The in vivo results suggest that Bay41-4109 nanoparticles have better bioavailability and would be a promising approach for oral delivery of Bay41-4109 for the treatment of HBV.
Sujet(s)
Chitosane/composition chimique , Systèmes de délivrance de médicaments , Nanoparticules , Pyridines/administration et posologie , Pyrimidines/administration et posologie , Administration par voie orale , Animaux , Biodisponibilité , Capside/effets des médicaments et des substances chimiques , Lignée cellulaire , Chimie pharmaceutique/méthodes , Réactifs réticulants/composition chimique , Vecteurs de médicaments/composition chimique , Humains , Mâle , Souris , Polyphosphates/composition chimique , Pyridines/composition chimique , Pyridines/pharmacocinétique , Pyrimidines/composition chimique , Pyrimidines/pharmacocinétique , Rats , Rat Sprague-Dawley , SolubilitéRÉSUMÉ
The objective of the current study was to establish an in vitro screen and a highly sensitive analytical assay to delineate key physicochemical properties that favor compound bioaccumulation in the L3 life stage of a Haemonchus contortus isolate. Time-dependent studies revealed that absorption and elimination kinetics during the first 6 hr of exposure were sufficient to achieve maximum bioaccumulation for the majority of compounds tested. In subsequent studies, the larvae were incubated for 6 hr in a medium containing 146 compounds (5 µM initial concentration), including both human and veterinary medicines, characterized by a broad range of physicochemical properties. Bioaccumulation of the compounds by the nematodes was determined, and multiple physicochemical descriptors were selected for correlation. Data analysis using Bayes classification model and partial least-square regression revealed that clogD7.4, rotatable bond, E-state, and hydrogen bond donor each correlated with compound bioaccumulation in H. contortus L3. The finding that lipophilicity was critical for transcuticle compound permeation was consistent with previous studies in other parasitic species and in adult H. contortus . The finding of additional physicochemical properties that contribute to compound conformational flexibility, polarity, and electrotopological state shed light on the mechanisms governing transcuticle permeation. The relatively poor correlation between transcuticle and transmembrane permeation indicated the distinct mechanisms of compound permeation, likely due to the different constituents, and their contributions to overall transport function, of the lipid membranes and the porous collagen barrier of the nematode cuticle. Our study, for the first time, establishes a high-throughput screen for compound bioaccumulation in a parasitic nematode and further elucidates physicochemical factors governing transcuticular permeation of compounds. Application of this methodology will help explain the basis for discrepancies observed in receptor binding and whole organism potency assays and facilitate incorporation of drug delivery principles in the design of candidate anthelmintics.
Sujet(s)
Anthelminthiques/pharmacocinétique , Haemonchus/métabolisme , Préparations pharmaceutiques/métabolisme , Animaux , Relation dose-effet des médicaments , Haemonchus/croissance et développement , Tests de criblage à haut débit , Larve/métabolisme , PerméabilitéRÉSUMÉ
OBJECTIVES: To characterize the effect of hepatitis C virus (HCV) polymerase intrinsic genetic heterogeneity on the inhibitory activity of nucleoside and non-nucleoside HCV polymerase inhibitors. METHODS: The sensitivity of genotype (GT) 1 HCV NS5B clinical isolates from treatment-naive patients to nucleoside and non-nucleoside polymerase inhibitors was assessed. The genetic diversity at the population level, as well as that of their quasispecies, was correlated with the observed reduced sensitivity to inhibitors. RESULTS: R1479 and NM107 (nucleoside analogues that have entered Phase 2 clinical trials as prodrugs R1626 and NM283, respectively) were similarly active across the tested clinical isolates. Resistance mutations to nucleoside analogues were not observed in any of the isolates. However, the activity of the non-nucleoside thumb II inhibitor NNI-1, palm I inhibitors NNI-2 and NNI-3, and palm II inhibitor HCV-796 was reduced across different isolates. This reduction in inhibitory activity for non-nucleoside inhibitors (NNIs) was, in most cases, correlated with the existence of known NNI resistance mutations in the NS5B polymerase population of the clinical isolates, as detected by population sequencing. Resistance mutations to NNIs were also observed at a low frequency within the clinical isolates' viral quasispecies that allowed for their rapid selection upon drug selective pressure. CONCLUSIONS: The higher frequency of known NNI resistance mutations or polymorphisms known to affect their antiviral potency when compared with the lack of detection of resistance mutations to the nucleoside analogues suggests a potential for primary reduced responsiveness as well as faster development of clinically significant resistance.
Sujet(s)
Antiviraux/pharmacologie , Résistance virale aux médicaments/génétique , Hepacivirus/effets des médicaments et des substances chimiques , Hepacivirus/génétique , Mutation faux-sens , Protéines virales non structurales/génétique , Séquence d'acides aminés , Substitution d'acide aminé , Cytidine/analogues et dérivés , Cytidine/pharmacologie , Hepacivirus/isolement et purification , Hépatite C chronique/virologie , Humains , Concentration inhibitrice 50 , Tests de sensibilité microbienne , Modèles moléculaires , Données de séquences moléculaires , Nucléosides pyrimidiques/pharmacologie , Analyse de séquence d'ADN , Réplication viraleRÉSUMÉ
Age-related macular degeneration (AMD) is one of the leading causes of loss of vision in the industrialized world. Attenuating the VEGF signal in the eye to treat AMD has been validated clinically. A large body of evidence suggests that inhibitors targeting the VEGFr pathway may be effective for the treatment of AMD. Recent studies using Src/YES knockout mice suggest that along with VEGF, Src and YES play a crucial role in vascular leak and might be useful in treating edema associated with AMD. Therefore, we have developed several potent benzotriazine inhibitors designed to target VEGFr2, Src, and YES. One of the most potent compounds is 4-chloro-3-{5-methyl-3-[4-(2-pyrrolidin-1-yl-ethoxy)phenylamino]benzo[1,2,4]triazin-7-yl}phenol ( 5), a dual inhibitor of both VEGFr2 and the Src family (Src and YES) kinases. Several ester analogues of 5 were prepared as prodrugs to improve the concentration of 5 at the back of the eye after topical administration. The thermal stability of these esters was studied, and it was found that benzoyl and substituted benzoyl esters of 5 showed good thermal stability. The hydrolysis rates of these prodrugs were studied to analyze their ability to undergo conversion to 5 in vivo so that appropriate concentrations of 5 are available in the back-of-the-eye tissues. From these studies, we identified 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate ( 12), a topically administered prodrug delivered as an eye drop that is readily converted to the active compound 5 in the eye. This topically delivered compound exhibited excellent ocular pharmacokinetics and poor systemic circulation and showed good efficacy in the laser induced choroidal neovascularization model. On the basis of its superior profile, compound 12 was advanced. It is currently in a clinical trial as a first in class, VEGFr2 targeting, topically applied compound for the treatment of AMD.
Sujet(s)
Dégénérescence maculaire/traitement médicamenteux , Solutions ophtalmiques/usage thérapeutique , Phénols/usage thérapeutique , Promédicaments/usage thérapeutique , Triazines/usage thérapeutique , Administration par voie topique , Animaux , Néovascularisation choroïdienne/traitement médicamenteux , Essais cliniques comme sujet , Modèles animaux de maladie humaine , Relation dose-effet des médicaments , Conception de médicament , Oeil/effets des médicaments et des substances chimiques , Oeil/effets des radiations , Lasers , Souris , Souris knockout , Modèles moléculaires , Structure moléculaire , Solutions ophtalmiques/composition chimique , Solutions ophtalmiques/pharmacocinétique , Phénols/composition chimique , Phénols/pharmacocinétique , Promédicaments/composition chimique , Promédicaments/pharmacocinétique , Relation structure-activité , Triazines/composition chimique , Triazines/pharmacocinétique , Récepteur-2 au facteur croissance endothéliale vasculaire/antagonistes et inhibiteurs , src-Family kinases/antagonistes et inhibiteursRÉSUMÉ
OBJECTIVE: The aim of this prospective study was to determine whether the resistive index (RI) ratio based on high-resolution spectral Doppler sonography would be useful in the differential diagnosis of small inflammatory and metastatic lymph nodes in rabbit models. METHODS: The infected and metastatic lymph node models we used were created by subcutaneously inoculating methicillin-susceptible Staphylococcus aureus and VX2 tumor cells respectively into the left hind limbs of 10 New Zealand White rabbits. High-resolution sonography was performed to investigate the popliteal fossa lymph nodes 2 weeks after the inoculation. The sizes, long-/short-axis ratios, and RI ratios (defined as the value of the peripheral RI relative to the central RI) of the nodes were evaluated with sonography and then compared with the histopathologic findings. RESULTS: No statistical differences were found between the volumes (mean +/- SD, 104 +/- 41 versus 87 +/- 24 mm(3); P > .05) and the long-/short-axis ratios (1.97 +/- 0.28 versus 2.03 +/- 0.26; P > .05) of 15 inflammatory and 14 metastatic lymph nodes. On spectral Doppler sonography, the RI ratio was higher in the metastatic lymph nodes than in the inflammatory lymph nodes. With an RI ratio higher than 1.2 as a diagnostic criterion for a metastatic lymph node, the sensitivity, specificity, and positive and negative predictive values of sonography were 71% (10/14), 80% (12/15), 76% (10/13), and 75% (12/16), respectively, with an area under the receiver operating characteristic curve value of 0.824. CONCLUSIONS: This experimental study confirms that RI ratio changes based on high-resolution spectral Doppler sonography are associated with histopathologic changes of metastatic and inflammatory lymph nodes during the initial stage in rabbits.
Sujet(s)
Noeuds lymphatiques/imagerie diagnostique , Métastase lymphatique/imagerie diagnostique , Échographie-doppler , Animaux , Traitement d'image par ordinateur , Inflammation/microbiologie , Noeuds lymphatiques/microbiologie , Études prospectives , Courbe ROC , Lapins , Répartition aléatoire , Sensibilité et spécificitéRÉSUMÉ
Combining the experimental efficiency of a murine hepatic in vitro drug biotransformation system with in silico genetic analysis produces a model system that can rapidly analyze interindividual differences in drug metabolism. This model system was tested by using two clinically important drugs, testosterone and irinotecan, whose metabolism was previously well characterized. The metabolites produced after these drugs were incubated with hepatic in vitro biotransformation systems prepared from the 15 inbred mouse strains were measured. Strain-specific differences in the rate of 16 alpha-hydroxytestosterone generation and irinotecan glucuronidation correlated with the pattern of genetic variation within Cyp2b9 and Ugt1a loci, respectively. These computational predictions were experimentally confirmed using expressed recombinant enzymes. The genetic changes affecting irinotecan metabolism in mice mirrored those in humans that are known to affect the pharmacokinetics and incidence of adverse responses to this medication.
Sujet(s)
Souris/génétique , Pharmacogénétique/méthodes , Testostérone/métabolisme , Animaux , Aryl hydrocarbon hydroxylases/génétique , Aryl hydrocarbon hydroxylases/métabolisme , Biotransformation , Cytochrome P-450 enzyme system/génétique , Cytochrome P-450 enzyme system/métabolisme , Famille-2 de cytochromes P450 , Glucuronosyltransferase/génétique , Glucuronosyltransferase/métabolisme , Foie/enzymologie , Foie/métabolisme , Préparations pharmaceutiques/métabolisme , Protéines recombinantes/métabolisme , Steroid hydroxylases/génétique , Steroid hydroxylases/métabolisme , Testostérone/analogues et dérivésRÉSUMÉ
This article describes a semi-quantitative reflectance near infrared (SQ-NIR) method for blend uniformity (BU) and content uniformity (CU) analyses in early stage formulation development. Applicability of the method depends upon three factors: separation of NIR signals of the active pharmaceutical ingredient (API) from placebo; strength of the signal; and a quantitative relationship between API concentration and NIR signal. Based on these three criteria, suitable NIR signals of the API, separated from those of placebo through suitable pretreatment of the spectra, can be used for BU and CU calculations without calibration models. The method was applied to an early stage formulation development project. Multiple batches of tablets were prepared and analyzed using the SQ-NIR method and a validated UV-VIS reference method. The SQ-NIR method was able to distinguish between batches that had satisfactory and unsatisfactory content uniformity and potency. In addition, effects of compression force and API particle size on the SQ-NIR results are discussed. It is proposed that the SQ-NIR method may be used as an independent test in early stage formulation development. The advantages and limitations of the method compared with traditional HPLC or UV-VIS methods are also discussed.
Sujet(s)
Préparations pharmaceutiques/composition chimique , Spectroscopie proche infrarouge , Technologie pharmaceutique/méthodes , Calibrage , Chimie pharmaceutique , Chromatographie en phase liquide à haute performance , Résistance à la compression , Préparations à action retardée , Études de faisabilité , Modèles chimiques , Taille de particule , Préparations pharmaceutiques/normes , Contrôle de qualité , Reproductibilité des résultats , Spectrophotométrie UV , ComprimésRÉSUMÉ
TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) is a novel multitargeted, orally active protein tyrosine kinase inhibitor. The inhibition constants (K(i)) of TG100435 against Src, Lyn, Abl, Yes, Lck, and EphB4 range from 13 to 64 nM. TG100435 has systemic clearance values of 20.1, 12.7, and 14.5 ml/min/kg and oral bioavailability of 74%, 23%, and 11% in mouse, rat, and dog, respectively. Four oxidation metabolites of TG100435 have been found in human, dog, and rat in vitro and in vivo. The ethylpyrrolidine N-oxide of TG100435 is the predominant metabolite (TG100855; [7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine) in human, dog, and rat. TG100855 is 2 to 9 times more potent than the parent compound. Flavin-containing monooxygenases are the primary enzymes mediating the biotransformation. Significant conversion of TG100435 to TG100855 has been observed in rat and dog after oral administration. Systemic exposure of TG100855 is 1.1- and 2.1-fold greater than that of TG100435 in rat and dog after oral dosing of TG100435. Since TG100435 is predominantly converted to the more potent N-oxide metabolite across species in vivo and in vitro, the overall tyrosine kinase inhibition in animal models may be substantially increased after oral administration of TG100435.
Sujet(s)
Inhibiteurs de protéines kinases/pharmacocinétique , Pyrrolidines/sang , Pyrrolidines/pharmacocinétique , Triazines/sang , Triazines/pharmacocinétique , Animaux , Biotransformation , Chiens , Femelle , Mâle , Souris , Souris de lignée BALB C , Microsomes du foie/métabolisme , Inhibiteurs de protéines kinases/sang , Rats , Rat Sprague-Dawley , src-Family kinases/antagonistes et inhibiteursRÉSUMÉ
We describe the identification of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine (3), a potent, orally active Src inhibitor with desirable PK properties, demonstrated activity in human tumor cell lines and in animal models of tumor growth.